Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Short term Debt (2017 - 2025)

Serina Therapeutics (SER) has disclosed Short term Debt for 9 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • Quarterly Short term Debt fell 72.4% to $2.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Sep 2025, down 72.4% year-over-year, with the annual reading at $7.6 million for FY2022, 7.09% up from the prior year.
  • Short term Debt hit $2.9 million in Q3 2025 for Serina Therapeutics, down from $10.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $22.9 million in Q2 2023 to a low of $1.5 million in Q3 2023.
  • Historically, Short term Debt has averaged $8.3 million across 5 years, with a median of $7.1 million in 2021.
  • Biggest five-year swings in Short term Debt: soared 1537.61% in 2021 and later tumbled 79.09% in 2023.
  • Year by year, Short term Debt stood at $7.1 million in 2021, then rose by 7.09% to $7.6 million in 2022, then crashed by 80.04% to $1.5 million in 2023, then soared by 585.58% to $10.5 million in 2024, then plummeted by 72.4% to $2.9 million in 2025.
  • Business Quant data shows Short term Debt for SER at $2.9 million in Q3 2025, $10.5 million in Q3 2024, and $10.4 million in Q2 2024.